These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 20713816

  • 1. Advanced biological therapies for diabetic foot ulcers.
    Kirsner RS, Warriner R, Michela M, Stasik L, Freeman K.
    Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
    [Abstract] [Full Text] [Related]

  • 2. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
    Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW.
    Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
    [Abstract] [Full Text] [Related]

  • 3. A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments.
    White R, McIntosh C.
    J Wound Care; 2009 Aug; 18(8):335-41. PubMed ID: 19862873
    [Abstract] [Full Text] [Related]

  • 4. Apligraf in the treatment of neuropathic diabetic foot ulcers.
    Edmonds M, European and Australian Apligraf Diabetic Foot Ulcer Study Group.
    Int J Low Extrem Wounds; 2009 Mar; 8(1):11-8. PubMed ID: 19189997
    [Abstract] [Full Text] [Related]

  • 5. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.
    Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L.
    Arch Surg; 2000 Jun; 135(6):627-34. PubMed ID: 10843357
    [Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [Abstract] [Full Text] [Related]

  • 7. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP, Plosker GL.
    BioDrugs; 2002 Jun; 16(6):439-55. PubMed ID: 12463767
    [Abstract] [Full Text] [Related]

  • 8. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
    Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II.
    Wounds; 2015 Apr; 27(4):83-91. PubMed ID: 25855851
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Wound Closure Rates Using a Human Fibroblast-derived Dermal Substitute Versus a Fetal Bovine Collagen Dressing: A Retrospective Study.
    Fitzgerald RH, Sabolinski ML, Skornicki M.
    Wound Manag Prev; 2019 Sep; 65(9):26-34. PubMed ID: 31702990
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Sep; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 11. New treatments in ulcer healing and wound infection.
    Edmonds M, Bates M, Doxford M, Gough A, Foster A.
    Diabetes Metab Res Rev; 2000 Sep; 16 Suppl 1():S51-4. PubMed ID: 11054889
    [Abstract] [Full Text] [Related]

  • 12. Comparison of characteristics and healing course of diabetic foot ulcers by etiological classification: neuropathic, ischemic, and neuro-ischemic type.
    Yotsu RR, Pham NM, Oe M, Nagase T, Sanada H, Hara H, Fukuda S, Fujitani J, Yamamoto-Honda R, Kajio H, Noda M, Tamaki T.
    J Diabetes Complications; 2014 Sep; 28(4):528-35. PubMed ID: 24846054
    [Abstract] [Full Text] [Related]

  • 13. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC, Boone D, Gendics C, Todd G.
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [Abstract] [Full Text] [Related]

  • 14. Treatment of diabetic foot ulcers using a blood bank platelet concentrate.
    Jeong SH, Han SK, Kim WK.
    Plast Reconstr Surg; 2010 Mar; 125(3):944-52. PubMed ID: 20195121
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers.
    Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA.
    Diabetes Care; 2001 Mar; 24(3):483-8. PubMed ID: 11289472
    [Abstract] [Full Text] [Related]

  • 16. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 17. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
    O'Meara S, Cullum N, Majid M, Sheldon T.
    Health Technol Assess; 2000 Jan; 4(21):1-237. PubMed ID: 11074391
    [Abstract] [Full Text] [Related]

  • 18. [New developments in the treatment of diabetic foot ulcers].
    Bakker K, Schaper NC.
    Ned Tijdschr Geneeskd; 2000 Feb 26; 144(9):409-12. PubMed ID: 10719543
    [Abstract] [Full Text] [Related]

  • 19. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A, Rogowski W.
    BMC Health Serv Res; 2009 Jul 10; 9():115. PubMed ID: 19591680
    [Abstract] [Full Text] [Related]

  • 20. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification independently predicts wound healing in diabetic foot ulcers.
    Hicks CW, Canner JK, Mathioudakis N, Sherman R, Malas MB, Black JH, Abularrage CJ.
    J Vasc Surg; 2018 Oct 10; 68(4):1096-1103. PubMed ID: 29622357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.